174 related articles for article (PubMed ID: 35168096)
1. S1P receptor modulators in Multiple Sclerosis: Detecting a potential skin cancer safety signal.
Stamatellos VP; Rigas A; Stamoula E; Lallas A; Papadopoulou A; Papazisis G
Mult Scler Relat Disord; 2022 Mar; 59():103681. PubMed ID: 35168096
[TBL] [Abstract][Full Text] [Related]
2. Disease-modifying agents for multiple sclerosis and the risk for reporting cancer: A disproportionality analysis using the US Food and Drug Administration Adverse Event Reporting System database.
Stamatellos VP; Siafis S; Papazisis G
Br J Clin Pharmacol; 2021 Dec; 87(12):4769-4779. PubMed ID: 33998034
[TBL] [Abstract][Full Text] [Related]
3. Molecular and neuroimmune pharmacology of S1P receptor modulators and other disease-modifying therapies for multiple sclerosis.
Kihara Y; Chun J
Pharmacol Ther; 2023 Jun; 246():108432. PubMed ID: 37149155
[TBL] [Abstract][Full Text] [Related]
4. Safety and Monitoring of the Treatment with Disease-Modifying Therapies (DMTs) for Multiple Sclerosis (MS).
Stamatellos VP; Papazisis G
Curr Rev Clin Exp Pharmacol; 2023; 18(1):39-50. PubMed ID: 35418296
[TBL] [Abstract][Full Text] [Related]
5. Association Between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database Analysis.
Dolladille C; Chrétien B; Peyro-Saint-Paul L; Alexandre J; Dejardin O; Fedrizzi S; Defer G
Neurotherapeutics; 2021 Jul; 18(3):1657-1664. PubMed ID: 34231126
[TBL] [Abstract][Full Text] [Related]
6. Abuse and dependence potential of sphingosine-1-phosphate (S1P) receptor modulators used in the treatment of multiple sclerosis: a review of literature and public data.
Schoedel KA; Kolly C; Gardin A; Neelakantham S; Shakeri-Nejad K
Psychopharmacology (Berl); 2022 Jan; 239(1):1-13. PubMed ID: 34773483
[TBL] [Abstract][Full Text] [Related]
7. An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis.
Dumitrescu L; Papathanasiou A; Coclitu C; Garjani A; Evangelou N; Constantinescu CS; Popescu BO; Tanasescu R
Expert Opin Pharmacother; 2023 Mar; 24(4):495-509. PubMed ID: 36946625
[TBL] [Abstract][Full Text] [Related]
8. Sphingosine 1-phosphate receptor modulators in multiple sclerosis treatment: A practical review.
Coyle PK; Freedman MS; Cohen BA; Cree BAC; Markowitz CE
Ann Clin Transl Neurol; 2024 Apr; 11(4):842-855. PubMed ID: 38366285
[TBL] [Abstract][Full Text] [Related]
9. Bioavailable central nervous system disease-modifying therapies for multiple sclerosis.
Hartung HP; Cree BAC; Barnett M; Meuth SG; Bar-Or A; Steinman L
Front Immunol; 2023; 14():1290666. PubMed ID: 38162670
[TBL] [Abstract][Full Text] [Related]
10. Oral Therapies for Multiple Sclerosis.
Faissner S; Gold R
Cold Spring Harb Perspect Med; 2019 Jan; 9(1):. PubMed ID: 29500302
[TBL] [Abstract][Full Text] [Related]
11. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.
McGinley MP; Cohen JA
Lancet; 2021 Sep; 398(10306):1184-1194. PubMed ID: 34175020
[TBL] [Abstract][Full Text] [Related]
12. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
13. Alopecia in Multiple Sclerosis Patients Treated with Disease Modifying Therapies.
Porwal MH; Salter A; Patel D; Obeidat AZ
J Cent Nerv Syst Dis; 2022; 14():11795735221109674. PubMed ID: 35769950
[TBL] [Abstract][Full Text] [Related]
14. Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis.
Roy R; Alotaibi AA; Freedman MS
CNS Drugs; 2021 Apr; 35(4):385-402. PubMed ID: 33797705
[TBL] [Abstract][Full Text] [Related]
15. Siponimod to treat secondary progressive multiple sclerosis.
Gajofatto A; Turatti M
Drugs Today (Barc); 2020 Jan; 56(1):37-46. PubMed ID: 32055804
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive review of varicella-zoster virus, herpes simplex virus and cryptococcal infections associated with sphingosine-1-phosphate receptor modulators in multiple sclerosis patients.
Sharma K; Chaudhary D; Beard K; Srivastava S; Khalid SH; Sriwastava S
Mult Scler Relat Disord; 2022 Mar; 59():103675. PubMed ID: 35168095
[TBL] [Abstract][Full Text] [Related]
17. Disproportional increase in psoriasis reports in association with B cell depleting therapies in patients with multiple sclerosis.
Porwal MH; Patel D; Maynard M; Obeidat AZ
Mult Scler Relat Disord; 2022 Jul; 63():103832. PubMed ID: 35512502
[TBL] [Abstract][Full Text] [Related]
18. Ozanimod for the treatment of relapsing forms of multiple sclerosis.
Kuczynski AM; Oh J
Neurodegener Dis Manag; 2021 Jun; 11(3):207-220. PubMed ID: 34011158
[TBL] [Abstract][Full Text] [Related]
19. Risk for Cardiovascular Adverse Events Associated With Sphingosine-1-Phosphate Receptor Modulators in Patients With Multiple Sclerosis: Insights From a Pooled Analysis of 15 Randomised Controlled Trials.
Zhao Z; Lv Y; Gu ZC; Ma CL; Zhong MK
Front Immunol; 2021; 12():795574. PubMed ID: 34950154
[TBL] [Abstract][Full Text] [Related]
20. Sphingosine 1-phosphate receptor modulators in multiple sclerosis.
Subei AM; Cohen JA
CNS Drugs; 2015 Jul; 29(7):565-75. PubMed ID: 26239599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
